Table 2.

Clinical trials using agents excluding sirolimus and paclitaxel

Tacrolimus	PRESENT I–III	Preliminary safety evaluation of nanoporous tacrolimus-eluting stents
	EVIDENT	The endovascular investigation determining the safety of new tacrolimus-eluting stent grafts
Everolimus	FUTURE I–IV	First used to underscore reduction in restenosis with everolimus
	SPIRITS-FIRST
M-Prednisolone implantation	IMPRESS	Immunosuppressive therapy for the prevention of restenosis after coronary artery stent
Dexamethasone	STRIDE	The study of antirestenosis with BiodivYsio dexamethasone-eluting stent
	EMPEROR	Evaluation of 9α-F-16 methylprednisolone (dexamethasone)-eluting stent on the reduction of restenosis
	DESIRE	Dexamethasone-eluting stent Italian registry
	SAFE	Sorin and aspirin following elective stenting
Mycophenolic acid	IMPACT	Inhibition with MPA of coronary restenosis trial
Batimastat	BATMAN	BiodivYsio batimastat SV stent versus balloon angioplasty for the reduction of restenosis in small coronary arteries
	BRILLIANT	Batimastat (BB-94) antirestenosis trial utilizing the BiodivYsio local drug delivery PC stent
Actinomycin hyperplasia	ACTION	Recruitment in the actinomycin-eluting stent improves outcomes by reducing neointimal
Angiopeptin	SWAN	Stent with angiopeptin
C-myc antisense	RESTEN-NG
Medtronic ABT-578	ENDEAVOR I–III	Randomized controlled trial to evaluate the safety and efficacy of the Medtronic AVE ABT-578-eluting driver™ coronary stent in de novo native coronary artery lesions
Abbott ABT-578	Zomaxx 1	Zomaxx coronary drug-eluting stent for de novo lesion in coronary arteries.
Estradiols	EASTER	Estrogen and stent to eliminate restenosis
NO donor compounds	NOBLESSE	Nitric oxide through biodegradable layer elective study for safety and efficacy
EPC antibodies	HEALING I–II	Healthy endothelial accelerated lining inhibits neointimal growth

Abbreviations: MPA, mycophenolic acid; PC, phosphorylcholine; SV, small-vessel.